The Medical Letter on Drugs and Therapeutics
Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis
The full article is available to subscribers Subscriber Login   
Revised 1/26/18: See Dosage and Administration third paragraph.

Obeticholic acid (Ocaliva – Intercept), a farnesoid X receptor agonist, has been approved by the FDA for treatment of primary biliary cholangitis; it is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in adults with an inadequate response to UDCA and as monotherapy in adults unable to tolerate UDCA. Obeticholic acid is the second drug to be approved for this indication; UDCA was the first.

PRIMARY BILIARY CHOLANGITIS — Primary biliary cholangitis, formerly called primary biliary cirrhosis, is a rare progressive autoimmune disease of the intralobular bile ducts that can lead to fibrosis, cirrhosis, and liver failure.1 It most commonly affects women >40 years old.

STANDARD TREATMENT — UDCA, a naturally occurring hydrophilic bile acid, replaces toxic hydrophobic bile acids that accumulate ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis
Article code: 1517d
 Electronic, downloadable article - $25